Hard-to-find insights from industry professionals on success strategies for developing the next generation of antiviral blockbuster drugs

Presented by industry professionals with a track record of discovering new drugs and treatments, Trends in Antiviral Drug Development describes successful development efforts for antiviral compounds and therapies that have entered the market or are currently in clinical trials. Viruses are ordered by their target tissue, in line with contemporary drug development that focuses on tissue-targeted therapeutics. Other key trends in antiviral therapy, such as the effort to develop long-acting drugs, are described for each virus type, enabling readers to follow the current and future state in this core area of contemporary drug development.

Trends in Antiviral Drug Development includes discussion on:

• Novel drugs against herpes viruses as well as the breakthrough drugs that cured HCV
• siRNA therapeutics, a new antiviral modality, and the drug candidates that are progressing toward achieving an HBV cure
• Drugs targeting viral entry, such as in HIV entry through attachment, co-receptor binding, and fusion
• Novel therapeutics against tropical diseases such as dengue fever and monkey pox

Trends in Antiviral Drug Development is an essential read for medicinal chemists, pharmaceutical chemists, virologists, and all professionals seeking to understand new ideas and approaches to combat the ever-expanding universe of viral infections.

Michael J. Sofia, Ph.D. is Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. where he established the programs in HBV-cure and coronavirus therapeutics.

Zhengqiang Wang, Ph.D. is Professor and Director of Chemistry at the Center for Drug Design, College of Pharmacy, University of Minnesota.